Shattuck Labs, Inc. Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Shattuck Labs, Inc. (STTK) had Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year of $267.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear · last filed 2022-11-09
- 2022-09-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $267.00K.
- 2022-06-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $534.00K.
- 2022-03-31: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $769.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year |
|---|---|
| 2022-09-30 | $267.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $534.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $769.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |